Near-term Pipeline

IMMvention's mission is to create a globally accessible therapy, benefiting patients with limited or no access to gene therapies. Currently in preclinical stage, IMM-4800 has exceptional drug-like properties differentiating it from other Bach1 inhibitors and positioning it for success.

​

Anticipated milestones include IND enabling studies in 2024 and Phase 1 clinical trials in 2025. Followed by Phase 2/3 trials and FDA approval submission in 2028, leading to a transformative solution for SCA patients worldwide.